What is Alzheimer’s disease?
In the weeks since a new Alzheimer’s drug was approved,have bombarded Dr. Alireza Atri with calls and emails about a treatment that has sparked both excitement and skepticism. They want to know if the drug might be right for them. Like many physicians, Atri has no easy answers. Alzheimer’s Association Chief Scientific Officer Dr. Maria Carrillo explains what Alzheimer’s disease is and how much it costs the U.S. health care system.
“It’s not a simple yes or no,” said the Banner Sun Health Research Institute neurologist in Arizona. It probably won’t be for a while. Doctors across the country are still trying to figure out who should receive the drug called Aduhelm, which, at best, slows the fatal disease marginally. Other drugs for Alzheimer’s disease only temporarily ease symptoms like memory problems, insomnia, and depression.
While some clinics have already started giving the drug, many providersor months to be ready. Insurers — including the biggest bill payer for this drug, Medicare — still need to determine which patients to cover for a treatment that could cost more than $50,000 a year. And doctors worry that emotions will affect decisions by patients and the drug.
“People are desperate. It’s a horrible disease,” said Stanford University’s Dr. Michael Greicius. Karl Newkirk hopes to start taking Aduhelm if his doctor gives the OK because he doesn’t see any other treatments worth trying. “It looks like the only star in the sky,” said the 80-year-old Sarasota, Florida, resident, who has early-stage Alzheimer’s. Newkirk’s doctor confirms he’s a good candidate for the drug. While the retired technology consultant is still fit enough to ride with his grandchildren at nearby Busch Gardens, he struggles with short-term memory loss. He wants to try Aduhelm, even though he knows the drug’s limits.
Michele Hall, 54, of Bradenton, Florida, also is eager to discuss the drug at her next appointment with an Alzheimer’s specialist. Hall was a former government attorney who had to quit her job after struggling with once-simple tasks like spelling, public speaking, and remembering deadlines. She was diagnosed with early Alzheimer’s last November by doctors at the . Hall calls Aduhelm “the first tiny glimmer of hope” that she’ll get more quality time with her husband and their three adult children.
BIOGEN’S STOCK SOARS AS ALZHEIMER’S DRUG COSTS REVEALED
“When you get that diagnosis, you wake up every morning and go, ‘Here I am, it’s ticking away, and I’m just waiting,'” she said. “Well, now you have something to look forward to.” Biogen’s Aduhelm is the first Alzheimer’s medication in nearly 20 years. Earlier this, its Food and Drug Administration approval triggered a swift backlash from many experts, including the agency’s outside advisers. They had warned that its supposed benefit relied on flimsy data. Three resigned over the FDA’s decision.
Aduhelm does not reverse their mental decline. It only slowed it in one study that was marred by hard-to-interpret results. The data were so murky that the doctors say the focus should be patients with an early diagnosis, like those who helped in the study.based on a different measure: its ability to get rid of harmful clumps of plaque in the brains of patients with early forms of the disease. The FDA approval isn’t limited to those early patients. Anyone with Alzheimer’s — at least theoretically — could get prescribed the drug. But advocacy groups like the Alzheimer’s Association and many
“I don’t want to see people pull theirto get this treatment,” said Dr. Babak Tousi, a Cleveland Clinic geriatrician who consulted with Biogen and helped run one of the testing sites for Aduhelm. This image provided by Biogen on Monday, June 7, 2021, shows a vial and packaging for the drug Aduhelm. On Monday, June 7, 2021, the Food and Drug Administration approved Aduhelm, the first new medication for Alzheimer’s in nearly 20 years, disregarding that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)
According to Dr. Ronald Petersen at the Mayo Clinic, safety will be a crucial consideration, which is developing its use guidelines for the drug. “We want to be conservative here,” said Petersen, an Alzheimer’s specialist who has consulted with most significant drugmakers in the field, including Biogen. About 40% of patients getting the entire drug dose in Biogen’s studies had swelling or tiny bleeds in the brain. While the side effects usually resolve, in rare cases, they lead to more severe bleeding that could cause brain injury or other dangerous complications.
Monitoring patients on the drug involves regular brain scans. That’s on top of a different type of scan to tell if patients have the brain plaque targeted by the drug. According to physicians, running all those tests could easily approach $10,000 in the first year. Insurers will likely require prior approval of those scans, which could delay care. And depending on coverage, patients still might be liable for thousands of dollars annually from the scans and treatments due to deductibles and other out-of-pocket costs.
Biogen says about 900 sites in the U.S. have the equipment and expertise to begin giving the drug, which requires monthly IVs immediately. The private Michigan Institute for Neurological Disorders has started treating early-stage Alzheimer’s patients. The institute said it would pick up most of the cost of an insurer ultimately denies coverage “because it’s a therapy we believe in,” a spokeswoman said. Meanwhile, Stanford’s Greicius, a neurologist and Alzheimer’s specialist, have no plans to prescribe Aduhelm.
“I don’t think there’s sufficient evidence that it works and plenty of evidence that it can harm patients,” he said. He said he plans to lay out a “compelling and compassionate” case for not wanting to give patients the medicine. But he worries that some patients may turn to a doctor who will provide it. The Cleveland Clinic’s Tousi said talking about expectations, bring someone back to who they were., and the side effects may counter some emotional pressure to give the drug to patients not suited for it. But part of the a patient is in an earlier stage of the disease than they are. He said they must understand that the medication will not
One likely consequence of Aduhelm’s approval is earlier screening and diagnosis for Alzheimer’s, a longtime aim of those who study the disease,or decades. But an earlier diagnosis combined with Aduhelm’s incremental may simply prolong the hardships of caring for someone with Alzheimer’s. “It could turn out that it increases your caregiver burden if it’s just slowing things down a little bit,” said Dr. Suzanne Schindler of Washington University in St. Louis. “I think it’s going to be disappointing for many people.” “What we wish cannot always be translated to real life,” he said.